Click on image to view larger version.

Figure 1 (Upper) Cyclic guanosine monophosphate (cGMP) levels in human endothelial cells after 24-h exposure to: native low-density lipoprotein (nLDL) (100 µg/ml), glycosylated low-density lipoprotein (glcLDL) (100 µg/ml), oxidized low-density lipoprotein (oxLDL) (100 µg/ml), glc-oxLDL (30 µg/ml), glc-oxLDL (100 µg/ml), glc-oxLDL (300 µg/ml), glc-oxLDL (second form) (100 µg/ml), and oxLDL (second form) (100 µg/ml). The 100- and 300-µg/ml doses of glc-oxLDL reduced significantly cGMP activity. *p < 0.05 vs. untreated cells; $p < 0.01 vs. untreated cells, nLDL and glcLDL; #p < 0.05 vs. oxLDL; **p < 0.001 vs. glc-oxLDL at 30 and 100 µg/ml, second form of glc-oxLDL and second form of ox-LDL; p < 0.0001 vs. untreated cells, nLDL and glcLDL. (Lower) The cGMP levels in cells stimulated with bradykinin and exposed for 24 h to the same lipoproteins as in the upper panel. *p < 0.001 vs. untreated cells; @p < 0.01 vs. nLDL; ¶p < 0.001 vs. nLDL and glcLDL; **p < 0.001 vs. oxLDL and glc-oxLDL at 30 µg/ml and second form of ox-LDL; p < 0.0001 vs. untreated cells, glcLDL, oxLDL, glc-oxLDL at 30 µg/ml.